Miranda Evans Appointed As Marketing Manager For Zylpha’s ‘Pay As You Bundle’ Software
Zylpha (www.zylpha.com) has appointed Miranda Evans as Marketing Manager for its widely acclaimed ‘Pay As…
Month: February 2021
Secureworks Unveils Secureworks Taegis™, XDR Advancements, and MSSP Partner Initiative to Strengthen Cybersecurity Community
Secureworks marshals software, brand and channel to protect enterprises and fight adversaries at scale Secureworks…
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development
SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and…
Update on vaccine production at BioNTech’s manufacturing site in Marburg
MAINZ, GERMANY, February 10, 2021 (GLOBE NEWSWIRE) – We started the manufacturing process at the…
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
Etesevimab and bamlanivimab administered together is authorized for treatment of recently diagnosed, mild to moderate…
PCI Biotech – release of the RNA Therapeutics Virtual Conference presentation
Oslo (Norway), 10 February 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing…
Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth
PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) — Biophytis (Euronext Growth Paris: ALBPS)…
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) — Biophytis (Euronext Growth Paris: ALBPS)…
Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer (iCCA)
Clinical proof of concept achieved for derazantinib monotherapy in FGFR2 gene fusion-positive iCCA 20.4% objective…
ObsEva Provides Business Outlook for 2021
GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX:…
Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering
LAKE FOREST, Ill., Feb. 10, 2021 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the…
Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM)…
Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a…
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage…
Autolus Announces Pricing of Public Offering
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical…
Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a…
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma…
Andy Hurley Named Agenus Chief Commercial Officer
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company…
Oncorus Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage…
Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Feb….